Acelyrin has raised $540 million in an initial public offering, the largest for a biotechnology startup since early 2021 and one of only a handful by young drugmakers this year. The company said Thursday it sold 30 million shares at $18 apiece, exceeding the projections it set earlier this week. It will start trading Friday on the Nasdaq under the ticker symbol “SLRN.” The pace of biotech IPOs has slowed considerably since 2021, when a record 104 startups flooded Wall Street, according to data compiled by BioPharma Dive.
Read the full article: Acelyrin Follows Kenvue with Largest IPO for a Biotech Startup since 2021 //
Source: https://www.biopharmadive.com/news/acelyrin-biotech-ipo-price-inflammation-drugs/649507